This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment. Rituximab (RTX) and omalizumab (OMZ) combination treatment may be well-tolerated and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results